CANCER PREVENTION The American Cancer Society (ACS) have updated their diet and physical exercise guidelines to advise avoidance of all alcohol, a change from previous guidance advising moderation.

American Cancer Society guideline for diet and physical activity for cancer prevention

Abstract

The American Cancer Society (ACS) publishes the Diet and Physical Activity Guideline to serve as a foundation for its communication, policy, and community strategies and, ultimately, to affect dietary and physical activity patterns among Americans. This guideline is developed by a national panel of experts in cancer research, prevention, epidemiology, public health, and policy, and reflects the most current scientific evidence related to dietary and activity patterns and cancer risk. The ACS guideline focuses on recommendations for individual choices regarding diet and physical activity patterns, but those choices occur within a community context that either facilitates or creates barriers to healthy behaviors. Therefore, this committee presents recommendations for community action to accompany the 4 recommendations for individual choices to reduce cancer risk. These recommendations for community action recognize that a supportive social and physical environment is indispensable if individuals at all levels of society are to have genuine opportunities to choose healthy behaviors. This 2020 ACS guideline is consistent with guidelines from the American Heart Association and the American Diabetes Association for the prevention of coronary heart disease and diabetes as well as for general health promotion, as defined by the 2015 to 2020 Dietary Guidelines for Americans and the 2018 Physical Activity Guidelines for Americans.

You may also be interested in these resources

Scientific Application Note

Biliary Tract Cancer Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

Oliver Klein, MD1,2; Damien Kee, MD1,3; Adnan Nagrial, MD4; etalBen Markman, MD5,6; Craig Underhill, MD7; Michael Michael, MD3; Louise Jackett, MD8; Caroline Lum, MD5; Andreas Behren, PhD2,9; Jodie Palmer, PhD2,9; Niall C. Tebbutt, MD1,10; Matteo S. Carlino, PhD4; Jonathan Cebon, PhD1,2,9 Author Affiliations JAMA Oncol. Published online July 30, 2020. doi:10.1001/jamaoncol.2020.2814 Key Points Question:  Is combination immunotherapy with nivolumab and ipilimumab associated with positive outcomes in patients with advanced biliary tract cancers?...

Share This